marketcaparena
Search

    ONC

    BeOne Medicines Ltd.

    Company overview

    Market capitalization
    —
    Employees
    12,000
    Latest publication
    2026-09-29
    About BeOne Medicines Ltd.

    BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company's commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; SYLVANT for the treatment of adult patients with multicentric castleman disease; BAITUOWEI for patients with BC in premenopausal and perimenopausal women, and cancer; and PARTRUVIX for the treatment of various solid tumors. Its clinical stage products comprise Sonrotoclax BGB-11417, a small molecule Bcl-2 inhibitor; BGB-16673, a BTK targeting chimeric degradation activation compound active against wild type and mutant BTK; BG-60366, an EGFR-targeted CDAC; BG-89894 (SYH2039), a MAT2A Inhibitor; BGB-58067, an MTA-Cooperative PRMT5 Inhibitor; BG-T187 and BG-C0902, an anti-EGFRxMET trispecific antibody; BGB-26808, a HPK-1 Inhibitor; BGB-C354, an anti-B7H3 ADC; Zanidatamab, a bispecific HER2-targeted antibody; BG-C137, an anti-FGFR2b ADC; BGB-53038, a Pan-KRAS Inhibitor; BGB-B2033, an anti-GPC3x4-1BB bispecific antibody; BGB-B3227, an anti-MUC1xCD16A bispecific antibody; BG-C477, an anti-CEAADC; BGB-43395, a CDK4 Inhibitor; BG-68501, a CDK2 Inhibitor; BG-C9074, an anti-B7H4 ADC; BGB-21447, a Bcl-2 Inhibitor; and BGB-45035, an IRAK4-targeted CDAC. It also has various preclinical programs. The company has agreements Amgen, BMS, Bio-Thera, EUSA Pharma, Luye Pharmaceutical, and Novartis. The company was formerly known as BeiGene, Ltd. and changed its name to BeOne Medicines AG in May 2025. BeOne Medicines AG was founded in 2010 and is based in Basel, Switzerland.

    Company website

    Financial statements

    Income Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ2 20262026-06-30 · USDQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ1 20212021-03-31 · USDQ3 20172017-09-30 · USD
    Total Revenue1,705,071,000USD1,513,438,000USD1,498,170,000USD1,412,284,000USD1,315,300,000USD1,117,279,000USD605,872,000USD220,213,000USD
    Cost Of Revenue174,530,000USD167,215,000USD142,422,000USD196,510,000USD164,606,000USD165,002,000USD32,685,000USD89,604,000USD
    Gross Profit1,530,541,000USD1,346,223,000USD1,355,748,000USD1,215,774,000USD1,150,694,000USD952,277,000USD573,187,000USD130,609,000USD
    Research Development612,280,000USD541,224,000USD615,423,000USD523,662,000USD524,896,000USD481,887,000USD320,726,000USD87,660,000USD
    Selling General Administrative593,214,000USD555,097,000USD555,290,000USD528,998,000USD537,913,000USD459,271,000USD—15,641,000USD
    Total Operating Expenses1,205,494,000USD1,096,321,000USD1,170,713,000USD1,052,660,000USD1,062,809,000USD941,175,000USD503,020,000USD15,704,000USD
    Operating Income325,047,000USD249,902,000USD185,035,000USD163,114,000USD87,885,000USD11,102,000USD70,167,000USD114,905,000USD
    Total Other Income Expense Net-12,588,000USD9,313,000USD-35,794,000USD-15,950,000USD11,664,000USD9,798,000USD-8,302,000USD-682,000USD
    Interest Income27,900,000USD27,664,000USD58,131,000USD3,029,000USD3,497,000USD5,848,000USD——
    Interest Expense39,739,000USD32,887,000USD58,234,000USD——7,002,000USD4,179,000USD1,785,000USD
    Income Before Tax312,459,000USD259,215,000USD149,241,000USD147,164,000USD99,549,000USD20,900,000USD61,865,000USD114,223,000USD
    Income Tax Expense75,452,000USD31,858,000USD82,739,000USD22,323,000USD5,229,000USD19,630,000USD-4,630,000USD-3,061,000USD
    Net Income237,007,000USD227,357,000USD66,502,000USD124,841,000USD94,320,000USD1,270,000USD66,495,000USD117,386,000USD
    Net Interest Income—-5,223,000USD-103,000USD3,029,000USD3,497,000USD5,848,000USD——
    Tax Provision—31,858,000USD82,739,000USD22,323,000USD5,229,000USD19,630,000USD——
    Net Income From Continuing Ops—227,357,000USD66,502,000USD124,841,000USD94,320,000USD1,270,000USD——
    Ebit—292,102,000USD212,987,000USD147,164,000USD99,549,000USD27,902,000USD70,167,000USD114,905,000USD
    Ebitda—333,246,000USD248,971,000USD184,448,000USD135,163,000USD60,706,000USD79,799,000USD116,205,000USD
    Depreciation And Amortization—41,144,000USD35,984,000USD37,284,000USD35,614,000USD32,804,000USD9,632,000USD1,300,000USD
    Reconciled Depreciation—41,144,000USD35,984,000USD37,284,000USD35,614,000USD32,804,000USD——
    Unclassified Operating Expenses——————182,294,000USD-87,597,000USD
    SourceDisclosureDeterministicFinalLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Income Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USD
    Total Revenue5,343,033,000USD
    Cost Of Revenue668,540,000USD
    Gross Profit4,674,493,000USD
    Research Development2,145,868,000USD
    Selling General Administrative2,081,489,000USD
    Total Operating Expenses4,227,357,000USD
    Operating Income447,136,000USD
    Interest Income70,505,000USD
    Interest Expense58,234,000USD
    Net Interest Income12,271,000USD
    Income Before Tax416,854,000USD
    Income Tax Expense129,921,000USD
    Tax Provision129,921,000USD
    Net Income286,933,000USD
    Net Income From Continuing Ops286,933,000USD
    Ebit475,088,000USD
    Ebitda616,774,000USD
    Depreciation And Amortization141,686,000USD
    Reconciled Depreciation141,686,000USD
    Total Other Income Expense Net-30,282,000USD
    SourceLegacy providerLegacy

    Balance sheet Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ2 20262026-06-30 · USDQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USD
    Total Assets9,175,615,000USD8,553,619,000USD8,188,573,000USD7,632,586,000USD6,298,394,000USD5,841,526,000USD5,920,910,000USD5,830,860,000USD
    Cash And Equivalents5,098,041,000USD———————
    Cash And Short Term Investments5,098,041,000USD4,791,676,000USD4,547,530,000USD4,036,868,000USD2,756,056,000USD2,516,411,000USD2,627,410,000USD2,701,933,000USD
    Short Term Investments0USD———————
    Long Term Investments66,056,000USD65,985,000USD61,678,000USD100,652,000USD119,475,000USD121,144,000USD128,933,000USD138,234,000USD
    Total Current Assets7,215,805,000USD6,601,280,000USD6,233,589,000USD5,664,477,000USD4,310,221,000USD3,896,492,000USD3,991,593,000USD3,911,736,000USD
    Other Current Assets328,984,000USD179,650,000USD190,971,000USD193,543,000USD171,168,000USD139,444,000USD160,091,000USD175,113,000USD
    Other Non Current Assets109,581,000USD———————
    Total Liabilities4,001,617,000USD———————
    Total Current Liabilities2,119,187,000USD1,811,510,000USD1,828,830,000USD2,368,425,000USD2,209,837,000USD1,983,721,000USD2,214,899,000USD2,025,332,000USD
    Other Current Liabilities40,217,000USD———————
    Other Non Current Liabilities77,644,000USD———————
    Total Stockholder Equity5,173,998,000USD4,760,442,000USD4,361,194,000USD4,129,326,000USD3,770,475,000USD3,499,513,000USD3,332,222,000USD3,436,073,000USD
    Total Equity Including Noncontrolling Interest5,173,998,000USD———————
    Short Long Term Debt190,896,000USD116,140,000USD57,293,000USD813,296,000USD808,394,000USD763,470,000USD851,529,000USD863,803,000USD
    Long Term Debt882,163,000USD962,515,000USD961,913,000USD139,571,000USD146,091,000USD160,157,000USD166,484,000USD187,513,000USD
    Net Receivables1,056,177,000USD948,364,000USD886,861,000USD902,379,000USD880,130,000USD745,977,000USD709,106,000USD603,014,000USD
    Inventory732,603,000USD681,590,000USD608,227,000USD531,687,000USD502,867,000USD494,660,000USD494,986,000USD431,676,000USD
    Property Plant Equipment Net1,789,273,000USD1,788,704,000USD1,789,862,000USD1,768,331,000USD1,766,408,000USD1,760,669,000USD1,657,238,000USD1,712,753,000USD
    Accounts Payable470,299,000USD423,546,000USD479,035,000USD383,676,000USD360,783,000USD364,498,000USD404,997,000USD307,532,000USD
    Short Term Debt21,953,000USD136,724,000USD134,705,574USD829,028,000USD825,644,000USD781,773,000USD869,105,000USD881,510,000USD
    Common Stock147,000USD144,000USD144,000USD144,000USD143,000USD140,000USD138,000USD138,000USD
    Retained Earnings-7,855,539,000USD-8,092,546,000USD-8,319,903,000USD-8,386,405,000USD-8,511,246,000USD-8,605,566,000USD-8,606,836,000USD-8,454,955,000USD
    Accumulated Other Comprehensive Income-25,370,000USD-53,482,000USD-78,184,000USD-101,256,999USD-113,698,000USD-142,321,000USD-148,988,000USD-83,525,000USD
    Intangible Assets—61,681,000USD62,704,000USD63,581,000USD64,890,000USD50,139,000USD129,765,000USD53,939,000USD
    Total Liab—3,793,177,000USD3,827,379,000USD3,503,260,000USD2,527,919,000USD2,342,013,000USD2,588,688,000USD2,394,787,000USD
    Other Current Liab—1,187,718,000USD1,173,464,426USD1,155,721,000USD908,498,000USD722,406,000USD879,963,000USD786,860,000USD
    Capital Stock—144,000USD144,000USD144,000USD143,000USD140,000USD138,000USD138,000USD
    Cash—4,791,676,000USD4,547,530,000USD4,036,868,000USD2,756,056,000USD2,516,411,000USD2,627,410,000USD2,701,933,000USD
    Net Debt—-3,642,767,000USD-2,547,721,472USD-3,016,882,000USD-1,730,381,000USD-1,519,586,000USD-1,547,544,000USD-1,600,456,000USD
    Short Long Term Debt Total—1,148,909,000USD1,999,808,528USD1,019,986,000USD1,025,675,000USD996,825,000USD1,079,866,000USD1,101,477,000USD
    Property Plant Equipment Gross—2,362,464,000USD2,244,643,000USD2,256,386,000USD2,219,439,000USD2,188,614,000USD2,056,343,000USD2,078,918,000USD
    Common Stock Shares Outstanding—115,771,333shares113,448,454shares114,519,258shares112,846,291shares111,173,325shares106,260,000shares104,698,659shares
    Non Current Assets Total—1,952,339,000USD1,954,984,000USD1,968,109,000USD1,988,173,000USD1,945,034,000USD1,929,317,000USD1,919,124,000USD
    Non Current Liabilities Total—1,981,667,000USD2,013,578,587USD1,134,835,000USD318,082,000USD358,292,000USD373,789,000USD369,455,000USD
    Non Current Liabilities Other—863,015,000USD879,773,000USD847,072,000USD23,487,000USD50,155,000USD70,498,000USD86,962,000USD
    Non Currrent Assets Other—35,969,000USD19,906,649USD35,545,000USD37,400,000USD13,082,000USD13,381,000USD14,198,000USD
    Net Working Capital—4,789,770,000USD4,404,759,000USD3,296,052,000USD2,100,384,000USD1,912,771,000USD1,776,694,000USD1,886,404,000USD
    Unclassified Current Liabilities—-52,618,000USD—-813,296,000USD-693,482,000USD-648,426,000USD-790,695,000USD-814,373,000USD
    Unclassified Non Current Liabilities—156,137,000USD171,892,587USD148,192,000USD148,504,000USD147,980,000USD136,807,000USD94,980,000USD
    Unclassified Equity—12,906,182,000USD12,758,993,000USD12,616,699,999USD12,395,133,000USD12,247,120,000USD12,087,770,000USD11,974,277,000USD
    Unclassified Non Current Assets——20,833,351USD—————
    SourceDisclosureDeterministicFinalLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Balance sheet Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20222022-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · CNYFY 20192019-12-31 · USDFY 20182018-12-31 · USD
    Total Assets8,188,573,000USD5,920,910,000USD5,805,275,000USD6,379,290,000USD8,535,525,000USD5,600,757,000CNY1,612,289,000USD2,249,684,000USD
    Intangible Assets62,704,000USD129,765,000USD108,855,000USD94,568,000USD103,348,000USD53,731,000CNY5,846,000USD52,230,000USD
    Other Current Assets190,971,000USD160,091,000USD219,606,000USD190,933,000USD253,439,000USD160,319,000CNY90,526,000USD96,486,000USD
    Total Liab3,827,379,000USD2,588,688,000USD2,267,948,000USD1,995,935,000USD2,402,962,000USD1,731,514,000CNY633,934,000USD496,037,000USD
    Total Stockholder Equity4,361,194,000USD3,332,222,000USD3,537,327,000USD4,383,355,000USD6,132,563,000USD3,869,243,000CNY962,205,000USD1,753,647,000USD
    Other Current Liab1,173,464,426USD879,963,000USD731,652,000USD562,872,000USD633,195,000USD459,579,000CNY177,010,000USD92,384,000USD
    Common Stock144,000USD138,000USD135,000USD135,000USD133,000USD118,000CNY79,000USD77,000USD
    Capital Stock144,000USD138,000USD135,000USD135,000USD133,000USD118,000CNY——
    Retained Earnings-8,319,903,000USD-8,606,836,000USD-7,962,050,000USD-7,080,342,000USD-5,076,527,000USD-3,552,749,000CNY-1,955,843,000USD-1,007,215,000USD
    Cash4,547,530,000USD2,627,410,000USD3,171,800,000USD3,869,564,000USD4,375,678,000USD1,381,950,000CNY618,011,000USD712,937,000USD
    Cash And Short Term Investments4,547,530,000USD2,627,410,000USD3,171,800,000USD4,534,815,000USD6,617,640,000USD4,650,675,000CNY982,739,000USD1,781,446,000USD
    Total Current Assets6,233,589,000USD3,991,593,000USD4,203,414,000USD5,207,078,000USD7,613,880,000USD4,960,690,000CNY1,172,696,000USD1,943,842,000USD
    Total Current Liabilities1,828,830,000USD2,214,899,000USD1,810,113,000USD1,468,528,000USD1,599,555,000USD1,075,199,000CNY310,312,000USD246,452,000USD
    Net Debt-2,547,721,472USD-1,547,544,000USD-2,241,615,000USD-3,272,889,000USD-3,681,034,000USD-819,986,000CNY-340,669,000USD-514,537,000USD
    Short Term Debt134,705,574USD869,105,000USD710,316,000USD353,010,000USD449,490,000USD348,910,000CNY10,814,000USD8,727,000USD
    Short Long Term Debt57,293,000USD851,529,000USD688,366,000USD328,969,000USD427,565,000USD335,015,000CNY——
    Short Long Term Debt Total1,999,808,528USD1,079,866,000USD930,185,000USD596,675,000USD694,644,000USD561,964,000CNY277,342,000USD198,400,000USD
    Long Term Debt961,913,000USD166,484,000USD197,618,000USD209,148,000USD202,113,000USD183,637,000CNY——
    Long Term Investments61,678,000USD128,933,000USD89,644,000USD91,779,000USD100,792,000USD49,344,000CNY——
    Net Receivables886,861,000USD709,106,000USD395,886,000USD198,984,000USD500,175,000USD60,403,000CNY70,878,000USD49,668,000USD
    Inventory608,227,000USD494,986,000USD416,122,000USD282,346,000USD242,626,000USD89,293,000CNY28,553,000USD16,242,000USD
    Accounts Payable479,035,000USD404,997,000USD315,111,000USD294,781,000USD262,400,000USD231,957,000CNY122,488,000USD113,283,000USD
    Property Plant Equipment Net1,789,862,000USD1,657,238,000USD1,371,788,000USD923,979,000USD662,507,000USD446,298,000CNY324,922,000USD194,235,000USD
    Property Plant Equipment Gross2,244,643,000USD2,056,343,000USD1,639,122,000USD1,144,091,000USD811,030,000USD519,652,000CNY——
    Accumulated Other Comprehensive Income-78,184,000USD-148,988,000USD-99,446,000USD-77,417,000USD17,950,000USD6,942,000CNY-8,000,999USD1,526,000USD
    Common Stock Shares Outstanding113,448,454shares105,288,000shares104,387,272shares103,133,044shares92,785,388shares83,471,675shares60,053,944shares55,442,601shares
    Non Current Assets Total1,954,984,000USD1,929,317,000USD1,601,861,000USD1,172,212,000USD921,645,000USD640,067,000CNY439,593,000USD305,842,000USD
    Non Current Liabilities Total2,013,578,587USD373,789,000USD457,835,000USD527,407,000USD803,407,000USD656,315,000CNY323,622,000USD249,585,000USD
    Non Current Liabilities Other879,773,000USD70,498,000USD170,846,000USD179,784,000USD269,629,000USD375,217,000CNY——
    Non Currrent Assets Other19,906,649USD13,381,000USD31,574,000USD61,886,000USD-55,535,000USD24,623,000CNY108,716,000USD29,726,000USD
    Net Working Capital4,404,759,000USD1,776,694,000USD2,393,301,000USD3,738,550,000USD6,014,325,000USD3,885,491,000CNY——
    Unclassified Non Current Assets20,833,351USD——-819,997,000USD54,889,000USD65,962,000CNY—29,542,000USD
    Unclassified Non Current Liabilities171,892,587USD136,807,000USD89,371,000USD138,475,000USD331,665,000USD97,461,000CNY323,622,000USD249,585,000USD
    Unclassified Equity12,758,993,000USD12,087,770,000USD11,598,553,000USD11,540,844,000USD11,190,874,000USD7,414,814,000CNY2,925,969,999USD2,759,259,000USD
    Unclassified Current Liabilities—-790,695,000USD-635,332,000USD-284,965,000USD-360,509,000USD-666,786,000CNY—13,918,000USD
    Short Term Investments——2,600,000USD665,251,000USD2,241,962,000USD3,268,725,000CNY364,728,000USD1,068,509,000USD
    Good Will———109,000USD109,000USD109,000CNY109,000USD109,000USD
    Other Assets———819,888,000USD————
    Current Deferred Revenue———213,861,000USD187,414,000USD366,524,000CNY—18,140,000USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Cash flow YTD

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ2 20262026-06-30 · USD
    Depreciation81,659,000USD
    Stock Based Compensation260,760,000USD
    Change To Account Receivables-192,876,000USD
    Change To Inventory-118,988,000USD
    Change To Liabilities-7,039,000USD
    Change In Working Capital-315,010,000USD
    Operating Cash Flow664,156,000USD
    Capital Expenditures-68,265,000USD
    Other Investing Activities11,952,000USD
    Unclassified Investing Cash Flow-38,550,000USD
    Investing Cash Flow-94,863,000USD
    Net Debt Issuance33,511,000USD
    Common Stock Issuance34,923,000USD
    Net Common Stock Issuance0USD
    Other Financing Activities-3,300,000USD
    Unclassified Financing Cash Flow-2,556,000USD
    Financing Cash Flow62,578,000USD
    Effect Of Forex Changes On Cash39,156,000USD
    Change In Cash671,027,000USD
    End Cash Flow5,280,674,000USD
    SourceDisclosureDeterministicFinal

    Cash flow Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ1 20262026-03-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USDQ2 20242024-06-30 · USDQ1 20242024-03-31 · USD
    Net Income228,034,921USD124,841,000USD94,320,000USD1,270,000USD-151,881,000USD-121,350,000USD-120,405,000USD-251,150,000USD
    Depreciation41,266,681USD37,284,000USD35,614,000USD32,804,000USD50,246,000USD71,292,000USD24,931,000USD25,293,000USD
    Stock Based Compensation123,355,000USD140,809,000USD150,809,000USD95,478,000USD107,617,000USD114,697,000USD130,637,000USD88,714,000USD
    Other Non Cash Items122,341,708USD-401,000USD-22,498,000USD-7,443,000USD88,040,000USD-6,737,000USD-17,338,000USD-16,070,000USD
    Change To Account Receivables-75,524,525USD-93,925,000USD-41,503,000USD-31,866,000USD-125,699,000USD-29,848,000USD-93,871,000USD-80,025,000USD
    Change To Inventory-72,052,203USD-28,836,000USD2,187,000USD3,987,000USD-79,384,000USD23,837,000USD1,315,000USD-37,264,000USD
    Change In Working Capital-189,706,977USD100,020,000USD5,353,000USD-78,027,000USD-18,862,000USD130,467,000USD-113,413,000USD-155,359,000USD
    Total Cash From Operating Activities201,936,333USD402,553,000USD263,598,000USD44,082,000USD75,160,000USD188,369,000USD-95,588,000USD-308,572,000USD
    Capital Expenditures-40,910,623USD-48,084,000USD-63,826,000USD-116,407,000USD-92,480,000USD-133,655,000USD-109,950,000USD-193,052,000USD
    Free Cash Flow161,025,710USD354,469,000USD199,772,000USD-72,325,000USD-17,320,000USD54,714,000USD-205,538,000USD-501,624,000USD
    Investments27,000USD-49,274,000USD-66,605,000USD-121,941,000USD-93,605,000USD-133,882,000USD-111,032,000USD-209,831,000USD
    Total Cashflows From Investing Activities-45,645,699USD-49,274,000USD-66,605,000USD-121,941,000USD-93,605,000USD-133,882,000USD-111,032,000USD-209,831,000USD
    Net Borrowings50,563,000USD-4,263,000USD26,076,000USD-97,136,000USD-13,318,000USD-3,561,000USD——
    Total Cash From Financing Activities68,836,643USD961,272,000USD35,025,000USD-33,777,000USD-4,523,000USD12,662,000USD23,017,000USD162,293,000USD
    Change In Cash243,831,391USD1,324,456,000USD255,495,000USD-108,156,000USD-74,681,000USD95,497,000USD-189,505,000USD-378,548,000USD
    Begin Period Cash Flow4,588,833,571USD2,786,086,000USD2,530,591,000USD2,638,747,000USD2,713,428,000USD2,617,931,000USD2,807,436,000USD3,185,984,000USD
    End Period Cash Flow4,832,664,962USD4,110,542,000USD2,786,086,000USD2,530,591,000USD2,638,747,000USD2,713,428,000USD2,617,931,000USD2,807,436,000USD
    Other Cashflows From Investing Activities-4,762,157USD-1,190,000USD-22,779,000USD-67,334,000USD-1,125,000USD-227,000USD-1,082,000USD-19,434,000USD
    Other Cashflows From Financing Activities-3,258,688USD885,000,000USD8,949,000USD63,359,000USD8,795,000USD16,223,000USD8,564,000USD14,791,000USD
    Unclassified Operating Cash Flow-123,355,000USD———————
    Unclassified Financing Cash Flow21,532,331USD80,535,000USD————14,453,000USD147,502,000USD
    Unclassified Investing Cash Flow—49,274,000USD86,605,000USD183,741,000USD93,605,000USD133,882,000USD111,032,000USD212,486,000USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Cash flow Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20222022-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · CNYFY 20192019-12-31 · USDFY 20182018-12-31 · USD
    Net Income286,933,000USD-644,786,000USD-881,708,000USD-2,003,815,000USD-1,413,354,000USD-1,600,523,000CNY-950,578,000USD-674,033,000USD
    Depreciation141,686,000USD171,762,000USD87,675,000USD66,278,000USD46,457,000USD31,789,000CNY18,617,000USD10,388,000USD
    Stock Based Compensation510,857,000USD441,618,000USD367,618,000USD303,162,000USD240,712,000USD183,481,000CNY134,154,000USD87,127,000USD
    Other Non Cash Items-12,767,874USD21,959,000USD-361,188,000USD3,306,000USD-13,108,000USD-20,985,000CNY67,603,000USD67,964,000USD
    Change To Account Receivables-164,954,000USD-329,443,000USD-188,306,000USD304,112,000USD-423,019,000USD10,363,000CNY-29,822,000USD-11,628,000USD
    Change To Inventory-93,168,000USD-91,496,000USD-140,948,000USD-56,689,000USD-153,333,000USD-58,906,000CNY-12,311,000USD-5,312,000USD
    Change In Working Capital191,402,874USD-157,167,000USD-370,539,000USD132,391,000USD-118,345,000USD150,584,000CNY-10,833,000USD-17,214,000USD
    Total Cash From Operating Activities1,127,580,000USD-140,631,000USD-1,157,453,000USD-1,496,619,000USD-1,298,723,000USD-1,283,461,000CNY-750,269,000USD-547,717,000USD
    Capital Expenditures-185,839,000USD-529,137,000USD-596,261,000USD-469,099,000USD-314,851,000USD-229,033,000CNY-158,612,000USD-140,836,000USD
    Free Cash Flow941,741,000USD-669,768,000USD-1,753,714,000USD-1,965,718,000USD-1,613,574,000USD-1,512,494,000CNY-908,881,000USD-688,553,000USD
    Investments-8,388,000USD-548,350,000USD60,004,000USD1,077,123,000USD640,659,000USD-3,168,366,000CNY——
    Total Cashflows From Investing Activities-276,155,000USD-548,350,000USD60,004,000USD1,077,123,000USD640,659,000USD-3,168,366,000CNY554,163,000USD-637,613,000USD
    Net Borrowings3,801,000USD145,076,000USD360,766,000USD-65,935,000USD101,533,000USD———
    Total Cash From Financing Activities1,059,451,000USD193,449,000USD416,478,000USD-18,971,000USD3,636,911,000USD5,202,826,000CNY85,680,000USD1,690,537,000USD
    Change In Cash1,970,900,000USD-547,237,000USD-689,053,000USD-507,850,000USD2,992,882,000USD769,230,000CNY-119,938,000USD501,111,000USD
    Begin Period Cash Flow2,638,747,000USD3,185,984,000USD3,875,037,000USD4,382,887,000USD1,390,005,000USD620,775,000CNY740,713,000USD239,602,000USD
    End Period Cash Flow4,609,647,000USD2,638,747,000USD3,185,984,000USD3,875,037,000USD4,382,887,000USD1,390,005,000CNY620,775,000USD740,713,000USD
    Other Cashflows From Investing Activities-81,928,000USD-39,336,000USD-36,440,000USD1,402,557,000USD-51,909,000USD-109,500,000CNY-69,000,000USD-108,851,000USD
    Other Cashflows From Financing Activities-27,060,957USD48,373,000USD55,712,000USD46,964,000USD92,762,000USD681,212,000CNY51,004,000USD29,662,000USD
    Unclassified Financing Cash Flow1,082,710,957USD————289,597,000CNY34,676,000USD1,660,875,000USD
    Unclassified Operating Cash Flow—25,983,000USD——-41,085,000USD-27,807,000CNY-9,232,000USD-21,949,000USD
    Unclassified Investing Cash Flow—568,473,000USD632,701,000USD-933,458,000USD366,760,000USD338,533,000CNY781,775,000USD-387,926,000USD
    Issuance Of Capital Stock——0USD0USD3,442,616,000USD4,232,017,000CNY——
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Operating metrics

    No operating metrics are currently published for this company.

    Revenue breakdown

    PeriodDimensionBusiness / regionRevenueCurrencySource
    Q2 2026Quarterly · 2026-06-30GeographyAll Other Countries Except China And United States Of America76,090,000USDDisclosure
    Q2 2026Quarterly · 2026-06-30GeographyChina506,021,000USDDisclosure
    Q2 2026Quarterly · 2026-06-30GeographyEurope208,755,000USDDisclosure
    Q2 2026Quarterly · 2026-06-30GeographyUnited States914,205,000USDDisclosure
    Q2 2026Quarterly · 2026-06-30ProductAmgen Royalty Revenue18,823,000USDDisclosure
    Q2 2026Quarterly · 2026-06-30ProductBLINCYTO36,537,000USDDisclosure
    Q2 2026Quarterly · 2026-06-30ProductBRUKINSA1,247,640,000USDDisclosure
    Q2 2026Quarterly · 2026-06-30ProductCollaboration Other1,498,000USDDisclosure
    Q2 2026Quarterly · 2026-06-30ProductKYPROLIS15,147,000USDDisclosure
    Q2 2026Quarterly · 2026-06-30ProductNovartis Broad Markets Revenue4,956,000USDDisclosure
    Q2 2026Quarterly · 2026-06-30ProductOther37,823,000USDDisclosure
    Q2 2026Quarterly · 2026-06-30ProductPOBEVCY9,633,000USDDisclosure
    Q2 2026Quarterly · 2026-06-30ProductTEVIMBRA228,515,000USDDisclosure
    Q2 2026Quarterly · 2026-06-30ProductXGEVA104,499,000USDDisclosure
    Q1 2026Quarterly · 2026-03-31GeographyAll Other Countries Except China And United States Of America65,213,000USD0001628280-26-030867
    Q1 2026Quarterly · 2026-03-31GeographyChina471,974,000USD0001628280-26-030867
    Q1 2026Quarterly · 2026-03-31GeographyEurope193,996,000USD0001628280-26-030867
    Q1 2026Quarterly · 2026-03-31GeographyUnited States782,255,000USD0001628280-26-030867
    Q1 2026Quarterly · 2026-03-31ProductAmgen Royalty Revenue18,297,000USD0001628280-26-030867
    Q1 2026Quarterly · 2026-03-31ProductCollaboration Other2,549,000USD0001628280-26-030867
    Q1 2026Quarterly · 2026-03-31ProductNovartis Broad Markets Revenue5,263,000USD0001628280-26-030867
    Q1 2026Quarterly · 2026-03-31ProductProduct1,487,329,000USD0001628280-26-030867
    Q4 2025Quarterly · 2025-12-31GeographyAll Other Countries Except China United States Of America And Switzerland53,355,000USD0001628280-26-011946
    Q4 2025Quarterly · 2025-12-31GeographyChina407,130,000USD0001628280-26-011946
    Q4 2025Quarterly · 2025-12-31GeographyEurope173,855,000USD0001628280-26-011946
    Q4 2025Quarterly · 2025-12-31GeographyUnited States863,830,000USD0001628280-26-011946
    FY 2025Yearly · 2025-12-31GeographyAll Other Countries Except China United States Of America And Switzerland171,809,000USD0001628280-26-011946
    FY 2025Yearly · 2025-12-31GeographyChina1,679,531,000USD0001628280-26-011946
    FY 2025Yearly · 2025-12-31GeographyEurope611,369,000USD0001628280-26-011946
    FY 2025Yearly · 2025-12-31GeographyUnited States2,880,324,000USD0001628280-26-011946
    FY 2025Yearly · 2025-12-31ProductCollaboration — Amgen Royalty Revenue40,733,000USD0001628280-26-011946
    FY 2025Yearly · 2025-12-31ProductCollaboration Other20,239,000USD0001628280-26-011946
    FY 2025Yearly · 2025-12-31ProductCollaboration Research And Development Service0USD0001628280-26-011946
    FY 2025Yearly · 2025-12-31ProductMaterial Rights Revenue0USD0001628280-26-011946
    FY 2025Yearly · 2025-12-31ProductNovartis Broad Markets Revenue17,598,000USD0001628280-26-011946
    FY 2025Yearly · 2025-12-31ProductProduct5,282,061,000USD0001628280-26-011946
    FY 2025Yearly · 2025-12-31ProductRight To Access Intellectual Property Revenue0USD0001628280-26-011946
    Q3 2025Quarterly · 2025-09-30GeographyAll Other Countries Except China And United States Of America50,967,000USD0001628280-25-049824
    Q3 2025Quarterly · 2025-09-30GeographyChina439,885,000USD0001628280-25-049824
    Q3 2025Quarterly · 2025-09-30GeographyEurope166,576,000USD0001628280-25-049824
    Q3 2025Quarterly · 2025-09-30GeographyUnited States754,856,000USD0001628280-25-049824
    Q3 2025Quarterly · 2025-09-30ProductAmgen Royalty Revenue12,169,000USD0001628280-25-049824
    Q3 2025Quarterly · 2025-09-30ProductCollaboration Other987,000USD0001628280-25-049824
    Q3 2025Quarterly · 2025-09-30ProductNovartis Broad Markets Revenue4,115,000USD0001628280-25-049824
    Q3 2025Quarterly · 2025-09-30ProductProduct1,395,013,000USD0001628280-25-049824
    Q2 2025Quarterly · 2025-06-30GeographyAll Other Countries Except China And United States Of America35,565,000USD0001651308-25-000133
    Q2 2025Quarterly · 2025-06-30GeographyChina432,924,000USD0001651308-25-000133
    Q2 2025Quarterly · 2025-06-30GeographyEurope152,384,000USD0001651308-25-000133
    Q2 2025Quarterly · 2025-06-30GeographyUnited States694,427,000USD0001651308-25-000133
    Q2 2025Quarterly · 2025-06-30ProductCollaboration — Amgen Royalty Revenue9,033,000USD0001651308-25-000133
    Q2 2025Quarterly · 2025-06-30ProductCollaboration — Novartis Broad Markets Revenue3,320,000USD0001651308-25-000133
    Q2 2025Quarterly · 2025-06-30ProductCollaboration Other871,000USD0001651308-25-000133
    Q2 2025Quarterly · 2025-06-30ProductProduct1,302,076,000USD0001651308-25-000133
    Q1 2025Quarterly · 2025-03-31GeographyAll Other Countries Except China And United States Of America31,922,000USD0001628280-26-030867
    Q1 2025Quarterly · 2025-03-31GeographyChina399,592,000USD0001628280-26-030867
    Q1 2025Quarterly · 2025-03-31GeographyEurope118,554,000USD0001628280-26-030867
    Q1 2025Quarterly · 2025-03-31GeographyUnited States567,211,000USD0001628280-26-030867
    Q1 2025Quarterly · 2025-03-31ProductAmgen Royalty Revenue5,519,000USD0001628280-26-030867
    Q1 2025Quarterly · 2025-03-31ProductCollaboration Other-292,000USD0001628280-26-030867
    Q1 2025Quarterly · 2025-03-31ProductNovartis Broad Markets Revenue3,522,000USD0001628280-26-030867
    Q1 2025Quarterly · 2025-03-31ProductOther Revenue8,749,000USD0001628280-26-030867
    Q1 2025Quarterly · 2025-03-31ProductProduct1,108,530,000USD0001628280-26-030867
    Q4 2024Quarterly · 2024-12-31GeographyAll Other Countries Except China And United States Of America30,694,000USDLegacy provider
    Q4 2024Quarterly · 2024-12-31GeographyChina362,868,000USDLegacy provider
    Q4 2024Quarterly · 2024-12-31GeographyEurope115,112,000USDLegacy provider
    Q4 2024Quarterly · 2024-12-31GeographyUnited States619,150,000USDLegacy provider
    FY 2024Yearly · 2024-12-31GeographyAll Other Countries Except China United States Of America And Switzerland78,810,000USD0001628280-26-011946
    FY 2024Yearly · 2024-12-31GeographyChina1,411,307,000USD0001628280-26-011946
    FY 2024Yearly · 2024-12-31GeographyEurope362,626,000USD0001628280-26-011946
    FY 2024Yearly · 2024-12-31GeographyUnited States1,957,498,000USD0001628280-26-011946
    Q3 2024Quarterly · 2024-09-30GeographyAll Other Countries Except China And United States Of America21,879,000USD0001628280-25-049824
    Q3 2024Quarterly · 2024-09-30GeographyChina375,993,000USD0001628280-25-049824
    Q3 2024Quarterly · 2024-09-30GeographyEurope98,265,000USD0001628280-25-049824
    Q3 2024Quarterly · 2024-09-30GeographyUnited States505,462,000USD0001628280-25-049824
    Q3 2024Quarterly · 2024-09-30ProductAmgen Royalty Revenue2,454,000USD0001628280-25-049824
    Q3 2024Quarterly · 2024-09-30ProductCollaboration Other530,000USD0001628280-25-049824
    Q3 2024Quarterly · 2024-09-30ProductNovartis Broad Markets Revenue5,168,000USD0001628280-25-049824
    Q3 2024Quarterly · 2024-09-30ProductOther Revenue8,152,000USD0001628280-25-049824
    Q3 2024Quarterly · 2024-09-30ProductProduct993,447,000USD0001628280-25-049824
    Q2 2024Quarterly · 2024-06-30ProductAmgen Royalty Revenue836,000USD0001651308-25-000133
    Q2 2024Quarterly · 2024-06-30ProductCollaboration8,020,000USD0001651308-25-000133
    Q2 2024Quarterly · 2024-06-30ProductCollaboration Other3,030,000USD0001651308-25-000133
    Q2 2024Quarterly · 2024-06-30ProductNovartis Broad Markets Revenue4,154,000USD0001651308-25-000133
    Q2 2024Quarterly · 2024-06-30ProductProduct921,146,000USD0001651308-25-000133
    Q1 2024Quarterly · 2024-03-31ProductChina Broad Markets Agreement4,347,000USD0001651308-24-000051
    Q1 2024Quarterly · 2024-03-31ProductCollaboration Research And Development Service0USD0001651308-24-000051
    Q1 2024Quarterly · 2024-03-31ProductProduct746,918,000USD0001651308-24-000051
    Q1 2024Quarterly · 2024-03-31ProductRight To Access Intellectual Property Revenue0USD0001651308-24-000051
    FY 2023Yearly · 2023-12-31GeographyAll Other Countries Except China United States Of America And Switzerland26,595,000USD0001628280-26-011946
    FY 2023Yearly · 2023-12-31GeographyChina1,101,951,000USD0001628280-26-011946
    FY 2023Yearly · 2023-12-31GeographyEurope202,014,000USD0001628280-26-011946
    FY 2023Yearly · 2023-12-31GeographyUnited States1,128,219,000USD0001628280-26-011946
    FY 2022Yearly · 2022-12-31GeographyAll Other Countries Except China And United States Of America10,006,000USD0001651308-25-000031
    FY 2022Yearly · 2022-12-31GeographyChina840,032,000USD0001651308-25-000031
    FY 2022Yearly · 2022-12-31GeographyEurope63,257,000USD0001651308-25-000031
    FY 2022Yearly · 2022-12-31GeographyUnited States502,626,000USD0001651308-25-000031
    FY 2022Yearly · 2022-12-31ProductCollaboration — Right To Access Intellectual Property Revenue104,994,000USD0001651308-23-000036
    FY 2022Yearly · 2022-12-31ProductCollaboration Other9,493,000USD0001651308-23-000036
    FY 2022Yearly · 2022-12-31ProductCollaboration Research And Development Service46,822,000USD0001651308-23-000036
    FY 2022Yearly · 2022-12-31ProductLicense0USD0001651308-23-000036

    Periods follow company fiscal calendars. Quarterly, annual and year-to-date amounts are shown separately. Missing values are not zero. Data may be delayed, incomplete or corrected; follow the disclosure links to verify figures.